QuantLogix ← CVS scorecard
📅 CVS Earnings Preview
CVS HEALTH CORPORATION
Next report (est.)
11/05/2026
Countdown
8 days
EPS growth YoY
+188.8%
Revenue growth YoY
+7.3%
Options-implied earnings move
±2.6%
The at-the-money straddle prices a move to roughly $94.81 or $89.97 from $92.39 by 10/30/2026.
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/05/2026 ±2.3% -5.1% under-priced
05/06/2026 ±2.3% +7.7% under-priced
02/10/2026 ±3.2% -0.1% over-priced
10/29/2025 ±1.9% -1.9% under-priced
07/31/2025 ±4.0% -0.3% over-priced
05/01/2025 ±2.0% +4.1% under-priced
02/12/2025 ±2.6% +14.9% under-priced
11/06/2024 ±2.4% +11.3% under-priced
Across these reports, options implied an average ±2.6% move vs an actual average of 5.7% — the stock stayed inside the implied band 25% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $2.31 $106.1B $3.0B
Q1 FY2026 $2.30 $100.4B $2.9B
Q4 FY2025 — $105.7B $2.9B
Q3 FY2025 $-3.13 $102.9B $-4.0B
Analyst posture
Buy / Strong Buy
28
Hold
4
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Neutral · 54/100 Full scorecard →
Get alerted before every CVS report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on CVS before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

CVS HEALTH CORPORATION (CVS) reports in 8 days, with the next report estimated for 11/05/2026. Across the last 8 reports, options priced an average ±2.6% earnings move while the stock actually moved 5.7% on average — the market has tended to under-price CVS's earnings risk. Fundamentals into the print: EPS up 188.8% year-over-year, revenue up 7.3%. QuantLogix's live 5-factor engine currently reads CVS as a neutral at 54/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →